Description General description A cell-permeable nitrophenylsulfonylbenzamide compound that is shown to bind anti-apoptotic Bcl-2 family members Bcl-2, Bcl-XL, and Bcl-w with high affinity (Ki ≤ 1 nM) and serves as a nonpeptidyl alternative to Bad-derived BH3 peptide (Cat. No. 197220) in preventing the binding and inhibition of the pro-apoptotic by the anti-apoptotic Bcl-2 family proteins. ABT-737 is demonstrated to fully reverse the blockage of Myr-Bid-induced cytochrome c release by Bcl-2 in mitochondria preparations from Bcl-2 overexpressing FL5.12 cells and effectively inhibit the growth of numerous cancer cells both in cultures in vitro (IC50 ≤100 nM against H146 and H1963) and in vivo (complete regression of H146 and H1963 in xenograft mice at 100 mg/kg/day, i.p.). Application of ABT-737 is also demonstrated to significantly reduce the disease severity in several murine models of autoimmunity. Also available as a 25 mM solution in DMSO (Cat. No. 197334). A cell-permeable nitrophenylsulfonylbenzamide compound that is shown to bind anti-apoptotic Bcl-2 family members Bcl-2, Bcl-XL, and Bcl-w with high affinity (Ki ≤1 nM) and serves as a nonpeptidyl alternative to Bad-derived BH3 peptide (Cat. No. 197220) in preventing the binding and inhibition of the pro-apoptotic by the anti-apoptotic Bcl-2 family proteins. ABT-737 is demonstrated to fully reverse the blockage of Myr-Bid-induced cytochrome c release by Bcl-2 in mitochondria preparations from Bcl-2 overexpressing FL5.12 cells and effectively inhibit the growth of numerous cancer cells both in cultures in vitro (IC50 ≤100 nM against H146 and H1963) and in vivo (complete regression of H146 and H1963 in xenograft mice at 100 mg/kg/day, i.p.). Application of ABT-737 is also demonstrated to significantly reduce the disease severity in several murine models of autoimmunity. Packaging 10 mg in Glass bottle Packaged under inert gas Warning Toxicity: Standard Handling (A) Reconstitution Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C. Other Notes Bardwell, P.D., et al. 2009. J. Immunol.182, 7482. Oltersdorf, T., et al. 2005. Nature435, 677.